MX2020004338A - Composiciones de peptidos tau fosforilados y sus usos. - Google Patents

Composiciones de peptidos tau fosforilados y sus usos.

Info

Publication number
MX2020004338A
MX2020004338A MX2020004338A MX2020004338A MX2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A
Authority
MX
Mexico
Prior art keywords
tau peptides
phosphorylated tau
compositions
peptides
conjugates
Prior art date
Application number
MX2020004338A
Other languages
English (en)
Inventor
Andreas Muhs
David Hickman
Elizabeth Anne Ramsburg
Marco Donata De
Anish Chakkumkal
Charlotte Sadaka
Jaap Goudsmit
Bosch Maria Pihlgren
Verhille Marija Vukicevic
Nicolas Piot
Saroj Raj Ghimire
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2020004338A publication Critical patent/MX2020004338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen liposomas que contienen peptidos tau, preferiblemente peptidos tau fosforilados, y conjugados que contienen peptidos tau, preferiblemente peptidos tau fosforilados, conjugados a un vehiculo inmunogenico; tambien se describen composiciones farmaceuticas y usos de los liposomas y/o conjugados para tratar o prevenir una enfermedad o trastorno neurodegenerativo, tal como la enfermedad de Alzheimer.
MX2020004338A 2017-10-25 2018-10-24 Composiciones de peptidos tau fosforilados y sus usos. MX2020004338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577157P 2017-10-25 2017-10-25
PCT/US2018/057286 WO2019084118A2 (en) 2017-10-25 2018-10-24 PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020004338A true MX2020004338A (es) 2020-10-14

Family

ID=64362628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004338A MX2020004338A (es) 2017-10-25 2018-10-24 Composiciones de peptidos tau fosforilados y sus usos.

Country Status (22)

Country Link
US (3) US11124552B2 (es)
EP (1) EP3700556A2 (es)
JP (2) JP2021501147A (es)
KR (1) KR20200077543A (es)
CN (2) CN111787942B (es)
AR (1) AR113792A1 (es)
AU (1) AU2018355325A1 (es)
BR (1) BR112020008168A2 (es)
CA (1) CA3079423A1 (es)
CL (2) CL2020001070A1 (es)
CO (1) CO2020006073A2 (es)
DO (1) DOP2020000135A (es)
EA (1) EA202091012A1 (es)
EC (1) ECSP20026986A (es)
IL (2) IL302108A (es)
JO (1) JOP20200103A1 (es)
MA (1) MA50465A (es)
MX (1) MX2020004338A (es)
PH (1) PH12020550432A1 (es)
SG (1) SG11202003556UA (es)
TW (2) TWI827557B (es)
WO (1) WO2019084118A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113792A1 (es) 2017-10-25 2020-06-10 Janssen Pharmaceuticals Inc Composiciones de péptidos tau fosforilados y sus usos
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) * 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
US20220339183A1 (en) * 2019-09-23 2022-10-27 Macquarie University Treatment of tauopathies
CA3161668A1 (en) 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
AU2022328342A1 (en) * 2021-08-12 2024-02-22 Ac Immune Sa Liposomes containing phosphorylated tau peptides for inducing sustained immune responses
WO2023152260A1 (en) * 2022-02-09 2023-08-17 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
WO2024015611A2 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. Tau peptide immunogen constructs

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
EA003739B1 (ru) 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
EP1301531A2 (en) 2000-07-11 2003-04-16 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
JP2005526497A (ja) 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
PL209696B1 (pl) 2002-04-19 2011-10-31 Univ Toronto Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
WO2004058239A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7901348B2 (en) 2003-12-12 2011-03-08 University Of Washington Catheterscope 3D guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP1879613B1 (en) 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
AU2006326283B2 (en) 2005-12-12 2012-01-19 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
US20100233095A1 (en) 2009-01-30 2010-09-16 Adlyfe, Inc. Conformationally dynamic peptides
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2010106127A2 (en) 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
JP2013500326A (ja) * 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
US20130022982A1 (en) 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
EP3231446A1 (en) 2010-04-19 2017-10-18 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
KR101854943B1 (ko) 2010-10-26 2018-05-04 에이씨 이뮨 에스.에이. 소수성 부분을 통해 변형된 펩티드를 포함하는 리포솜 기반 구조체
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经***科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
US20140314837A1 (en) 2011-09-23 2014-10-23 Ac Immune S. A. Vaccine Therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第１３族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第１３族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
CN107074965B (zh) 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
MA44955A (fr) 2015-06-05 2019-03-20 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
WO2017030913A2 (en) 2015-08-14 2017-02-23 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
AU2017259038B2 (en) 2016-05-02 2024-05-23 Prothena Biosciences Limited Antibodies recognizing Tau
AU2017373889A1 (en) 2016-12-07 2019-06-06 Ac Immune Sa Anti-Tau antibodies and methods of use
AR113792A1 (es) * 2017-10-25 2020-06-10 Janssen Pharmaceuticals Inc Composiciones de péptidos tau fosforilados y sus usos
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
SG11202108312PA (en) * 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.

Also Published As

Publication number Publication date
AU2018355325A1 (en) 2020-05-07
TW201932138A (zh) 2019-08-16
CN111787942B (zh) 2024-03-29
MA50465A (fr) 2020-09-02
US11958889B2 (en) 2024-04-16
IL273980A (en) 2020-05-31
US20200376078A1 (en) 2020-12-03
US20210388044A1 (en) 2021-12-16
CL2021000217A1 (es) 2021-07-02
JOP20200103A1 (ar) 2020-05-06
CA3079423A1 (en) 2019-05-02
CN111787942A (zh) 2020-10-16
US20190119341A1 (en) 2019-04-25
ECSP20026986A (es) 2020-06-30
JP2021501147A (ja) 2021-01-14
US11124552B2 (en) 2021-09-21
EP3700556A2 (en) 2020-09-02
IL302108A (en) 2023-06-01
BR112020008168A2 (pt) 2020-10-27
JP2023071688A (ja) 2023-05-23
TWI827557B (zh) 2024-01-01
AR113792A1 (es) 2020-06-10
KR20200077543A (ko) 2020-06-30
CO2020006073A2 (es) 2020-05-29
TW202333768A (zh) 2023-09-01
WO2019084118A3 (en) 2019-06-06
EA202091012A1 (ru) 2020-08-27
CN117298259A (zh) 2023-12-29
SG11202003556UA (en) 2020-05-28
WO2019084118A2 (en) 2019-05-02
PH12020550432A1 (en) 2021-04-26
CL2020001070A1 (es) 2020-08-28
DOP2020000135A (es) 2021-04-30

Similar Documents

Publication Publication Date Title
MX2020004338A (es) Composiciones de peptidos tau fosforilados y sus usos.
CL2020002024A1 (es) Moduladores de calpaínas y usos terapeuticos de los mismos. (divisional solicitud 201900793)
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
CL2019002240A1 (es) Dendrímeros terapéuticos.
AR093705A1 (es) Depsipeptido y sus usos
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
ECSP17069696A (es) Compuestos novedosos
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CU20210077A7 (es) Extractos bacterianos estables como fármacos
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
BR112018016715A2 (pt) ?formulações de oritavancina?
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
CL2017003500A1 (es) Síntesis total de shishijimicina a y sus análogos
WO2018094035A3 (en) Ligand ionophore conjugates
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза